Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

BACKGROUND AND AIMS: Irritable bowel syndrome (IBS) is a chronic relapsing disorder characterized by abdominal pain-discomfort and altered bowel habits. The IBS-diarrhoea predominant subtype (IBS-D) is defined as >25% of bowel movements representing type 6 or 7 of the Bristol Stool Form Scale. Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Dwaipayan Sarathi, Hazra, Avijit, Sil, Amrita, Pain, Shantasil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857390/
https://www.ncbi.nlm.nih.gov/pubmed/31742138
http://dx.doi.org/10.4103/jfmpc.jfmpc_522_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857390/
https://www.ncbi.nlm.nih.gov/pubmed/31742138
http://dx.doi.org/10.4103/jfmpc.jfmpc_522_19

Ejemplares similares